Pembrolizumab + Cisplatin + 5-fluorouracil + Oxaliplatin + Capecitabine + Placebo for Pembrolizumab
Phase 3Withdrawn 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Stomach Neoplasms
Conditions
Stomach Neoplasms
Trial Timeline
Nov 8, 2018 → Nov 29, 2024
NCT ID
NCT04859582About Pembrolizumab + Cisplatin + 5-fluorouracil + Oxaliplatin + Capecitabine + Placebo for Pembrolizumab
Pembrolizumab + Cisplatin + 5-fluorouracil + Oxaliplatin + Capecitabine + Placebo for Pembrolizumab is a phase 3 stage product being developed by Merck for Stomach Neoplasms. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04859582. Target conditions include Stomach Neoplasms.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03675737 | Phase 3 | Completed |
| NCT04859582 | Phase 3 | Withdrawn |
Competing Products
20 competing products in Stomach Neoplasms